Photo from archive.org
The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone… Click to show full abstract
The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control. This article is protected by copyright. All rights reserved.
Keywords:
antidiabetic therapies;
fda guidance;
cardiovascular risk
Journal Title: Diabetes
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!